Cognitive remediation therapy in schizophrenia

Randomised controlled trial

TIL WYKES, CLARE REEDER, SABINE LANDAU, BRIAN EVERITT, MARTIN KNAPP, ANITA PATEL and RENEE ROMEO

Background  Cognitive difficulties are prevalent in people with a diagnosis of schizophrenia and are associated with poor long-term functioning.

Aims  To evaluate the effectiveness of cognitive remediation therapy on cognitive difficulties experienced by people with schizophrenia.

Method  Participants with a diagnosis of schizophrenia, a social behaviour problem and a cognitive difficulty (n=85) were randomised to 40 sessions of cognitive remediation or treatment as usual in a single-blind randomised controlled trial. Working memory, cognitive flexibility and planning were measured at weeks 0, 14 and 40.

Results  There were durable improvements in working memory (advantage 1.33 points, 95% CI 0.43–2.16, standardised effect size 0.34) as well as an indication of improvement in cognitive flexibility. Memory improvement predicted improvement in social functioning. Costs were lower in the cognitive remediation group following therapy but rose at follow-up. However, cost-effectiveness analyses showed that improvements in memory were achieved at little additional cost.

Conclusions  Cognitive remediation therapy is associated with durable improvements in memory, which in turn are associated with social functioning improvements in people with severe mental illness.

Declaration of interest  None.

Both longitudinal and cross-sectional studies of patients with a diagnosis of schizophrenia suggest that cognitive performance is poor and remains poor over the course of the disorder, and that such deficits, particularly in memory, limit functioning outcomes and the rehabilitation of particular life skills such as work and social functioning (Green et al, 2000; Wykes & Reeder, 2005). In order to remove this rate limitation a new rehabilitation technology, cognitive remediation therapy, was developed with the aim of improving cognition and thereby increasing the likelihood of improved functioning outcomes. Cognitive remediation therapy is an umbrella term for a number of different interventions defined by their procedural characteristics such as use of a therapist, use of a computer and the method of training. There is some evidence of efficacy for face-to-face therapy from small studies; however, no large study has investigated the effects and cost-effectiveness of face-to-face therapy. In addition, studies have been limited to people who fulfilled narrow entry criteria in terms of their cognitive difficulties. It is, therefore, not yet possible to identify whether this form of cognitive therapy will have an impact on those with a spectrum of cognitive difficulties. The key effectiveness questions for cognitive remediation therapy concern its likely success when the recipients have a variety of cognitive difficulties as well as a diagnosis of schizophrenia, and whether any cognitive improvements have an impact on functioning.

METHOD

Study design  We carried out a single-blind, randomised controlled trial of a new therapy to improve cognition in people with schizophrenia by comparing a group receiving 40 sessions of therapy with a group who received only usual treatment. We tested whether cognitive skills improved in the intervention group and whether this improved cognitive skill led to improvements in symptoms, social functioning and self-esteem. After baseline assessment, participants were randomised to either treatment or control and were then assessed at 14 weeks (post-therapy) and 40 weeks (6 months after therapy discontinuation). The trial registration number is ISRCTN44277627.

Inclusion and exclusion criteria  We recruited participants from local community mental health teams in the South London and Maudsley National Health Service Trust in a structured geographical rotation from February 1999 to December 2002. Patients were included if they had been in contact with the services for at least 1 year, were at least 17 years old, had a diagnosis of schizophrenia based on DSM-IV (American Psychiatric Association, 1994) and evidence of both social functioning, defined as a problem on the Social Behaviour Scale (SBS; Wykes & Sturt, 1986), and thinking difficulties. Thinking difficulties were defined as a poor memory score on the Rivermead scale (Wilson et al, 1999), and/or cognitive flexibility on the Wisconsin Card Sorting Test (WCST; Heaton et al, 1993) below the 16th centile, and/or a poor score on the Hayling Sentence Completion Test (Burgess & Shallice, 1996).

Therapy  Several programmes are available to test, but the one chosen was first developed in Australia (Delahunty & Morice, 1993) and incorporates the teaching of strategic information processing, which has been identified as the training more likely to produce larger cognitive benefits following analysis in the most comprehensive review (Krabbe & Aleman, 2003). This is a promising programme because, unlike the others, it has been shown to have specific effects when tested in a randomised controlled trial against another psychosocial programme (Wykes et al, 1999, 2003).

Therapy consisted of 40 face-to-face sessions, each involving a number of paper and pencil tasks that provide practice in a variety of cognitive skills that are set out in a manual (Delahunty et al, 2002). Therapy was delivered to individuals on at least 3 days per week until 40 sessions were completed. The therapists were graduate psychologists who had followed a dedicated training programme involving theory,
observation and supervised practice sessions. The therapy is based on three general clinical principles:

(a) teaching (or facilitating learning of) new efficient information processing strategies;
(b) individualising therapy;
(c) aiding the transfer of cognitive gains into the real world.

The programme consists of three modules: cognitive flexibility, working memory and planning (Delahunt et al., 2002; Reeder et al., 2004). In each module there is a series of tasks, graded from ‘extremely easy’ to ‘easy’, so that an errorless learning environment can be provided. In the cognitive flexibility module, patients are given practice in engagement, disengagement and re-engagement activities for a particular cognitive set or between two sets. The working memory module requires the person to maintain two sets of information simultaneously and to carry out transformations on a held information set. The planning module consists of tasks in which the participant has to plan a sequence of moves to acquire a goal. The emphasis in this module is to organise information and to create and use sub-goals. One major change from the therapy as administered in previous studies (e.g. Wykes et al., 1999) was the emphasis of therapists on the possible uses of the strategies being taught within the participants’ own lives, for example in going shopping. This was achieved by encouraging the participants to reflect on how the skills learnt in therapy might be used to achieve real-life goals (see Wykes & Reeder, 2005 for further details).

Therapist fidelity was checked against the records completed at the end of each session, the task sheets produced during the sessions and by direct observation. Participants did receive therapy that complied with the manual, and the majority of the tasks were delivered for most participants. These high levels of fidelity were maintained and supported by weekly supervision.

Outcome measures
The three main outcome measures were:

(a) cognitive flexibility – categories achieved from the Wisconsin Card Sorting Test;
(b) planning – the profile score from the Behavioural Assessment of the Dysexecutive Syndrome (BADS; Wilson et al., 1996);
(c) working memory – total raw score on the Digit Span test of the Wechsler Adult Intelligence Scale III (WAIS–III; Wechsler, 1981).

In addition to the main outcomes we also collected data on symptoms from the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987), a self-esteem score from the Rosenberg Self-Esteem Scale (SES; Rosenberg, 1965) and level of social functioning from the Social Behaviour Scale (Wykes & Sturt, 1986). Health, social care and criminal justice system resource use were assessed using the Client Service Receipt Inventory (Beecham & Knapp, 1992) retrospectively from healthcare staff or records, and/or by participant self-report for the relevant assessment intervals. Unit costs (at 2000–2001 levels) based on national statistics were attached to all resource use to calculate total health and societal costs.

Procedure
All participants gave written informed consent prior to inclusion in the trial. After baseline assessment participants were randomly allocated by an independent statistician using a concealed randomisation method. Participants assigned to the cognitive remediation condition received therapy within 2 weeks of randomisation. Therapy continued for 40 sessions (approximately 12 weeks). In addition to the assessments on outcome measures, data were also collected on clinical history, demographic characteristics and premorbid IQ as assessed on the National Adult Reading Test (NART; Nelson & Willison, 1991).

Protecting against bias
Symptoms were rated by a psychiatrist unaware of group allocation, who was based in a different building to the other researchers and the independent site of randomisation. Participants were informed that they should not reveal their group allocation prior to each assessment and none did so for the symptom assessment. Cognitive data were collected by independent assessors who, although initially masked to group allocation, were not unaware of all allocations since some participants revealed their randomisation group at the post-treatment assessment point. However, as these data were collected either by computer or under clear guidance and instruction, the effect of the revealing of group allocation is unlikely to be significant. Social behaviour data were collected from keyworker or relative informants who were independent of the trial but not masked to group allocation.

Sample size and power of the study
Previous studies of this programme have suggested that there will be improvement in both groups with repeated testing over time. We have therefore used the outcome data reported by Wykes et al. (1999) to define a clinically significant difference as 71% of the experimental group improving compared with 31% of the control group. This difference is considered to be a clinically significant difference in proportions considering the amount of therapy time that would need to be allocated. This is an odds ratio of 0.184. We estimated that a sample of 29 people per group would have 80% power at the 5% significance level to detect this difference. The sample size was increased to 42 to take into account a possible 30% withdrawal rate.

Statistical analyses
Participants were analysed in the treatment group to which they were randomised irrespective of whether they adhered to their treatment. All outcome measures were analysed using linear mixed modelling with models fitted using restricted maximum likelihood methods based on the assumption of normality for the error terms. Models included baseline values of the outcome measure, and symptoms considered possibly to affect cognitive outcome following therapy as explanatory variables. The experimental factors, randomisation group (therapy or control) and time (post-treatment or follow-up) were included in the model as fixed main effects and a group × time interaction. In addition, random effects for participants were included. A significant interaction term implies a differential intervention effect at the two post-therapy time points. Where the interaction effect was not significant, the corresponding model was refitted excluding this term, to assess the overall group effect. A main effect of randomisation group would then be interpreted as an effect of the intervention therapy consistent across both time points.

We also chose to investigate whether the effects of treatment meant that cognitive scores were then within the normal range. This differential improvement rate was tested by chi-squared tests for each
main outcome measure, by investigating the changes to normal scores of all those who had abnormal scores at baseline.

Costs
Differences in mean costs and 95% confidence intervals were obtained using non-parametric bootstrapping techniques to account for any non-normality in their distribution (1000 repetitions), using Stata version 8.0 for Windows. Costs (including the costs of therapy where applicable) were adjusted for baseline values of equivalent cost categories and baseline total PANSS score.

To allow a cost-effectiveness analysis based on a more meaningful interpretation of the primary outcome measure, we also compared the percentage of ‘improvers’ in each group based on WAIS–III Digit Span raw scores (improvers were defined as those gaining 2 points or more on this measure since baseline). This was based on a relatively large effect size of 0.7 and was chosen because recent studies suggest that improvements of this size may contribute to functional improvements (Bryson & Bell, 2003). For cost-effectiveness ratios based on ‘improvers’, percentages were also compared using non-parametric bootstrapping, and were adjusted for baseline WAIS–III Digit Span raw score and total PANSS score.

It was not necessary to calculate ratios in scenarios in which one group had both lower costs and better outcomes, as the decision regarding which treatment is preferred is intuitively clear. Where one group had both higher costs and better outcomes, the additional cost per additional 1% of improvers on the WAIS–III Digit Span raw score was calculated by dividing the mean difference in costs by the mean difference in percentage of improvers.

Mechanisms underlying social functioning change
Finally, cognitive change is predicted to have an impact on social functioning. In order to test this model a regression was carried out with follow-up social functioning outcome as the dependent variable, therapy group as a factor, and cognitive change over the treatment period and baseline levels of social functioning and symptoms as covariates. The model first tested a group-dependent cognition effect by means of an interaction between cognitive change and group. If the interaction effect was not significant then it was excluded and the model rerun to assess the overall effect of cognitive change on functioning.

RESULTS
Eighty-five participants were recruited to the trial, of whom 43 were randomised to cognitive remediation therapy and 42 to the control condition (Fig. 1). Nearly three-quarters of the sample were men (73%; n=62) and the mean age was 36 years; 47% (n=40) were living in independent accommodation or with their family. Most had no experience of a stable relationship, and 40% (n=34) had never lived independently. About half (n=44) had been in touch with the psychiatric services for at least 10 years. The participants were therefore severely impaired in overall functioning, although some people had made some achievements such as marrying or having independent living arrangements.

Not all participants agreed to complete all assessments for a variety of reasons, including delusional ideation as well as refusal. There was no difference between the groups in the rate of withdrawals ($\chi^2=0.047$, d.f.=1, $P=1.0$) and none of the potential baseline variables (cognition outcomes, self-esteem, social behaviour or symptoms) predicted withdrawal from the study (probability levels all above 0.16). Overall, the intervention group participants received a mean of 36.9 (0–40) sessions of therapy, with a mean of 3.8 per week for those who started therapy, and at least 30 sessions being received by 93% of the sample.

Table 1 shows the types of primary medications and the mean dosage in chlorpromazine equivalents for those whose primary medication was a typical antipsychotic. Two people in the therapy group and one person in the control group received both typical and atypical medication. Of those prescribed typical antipsychotics, 11 received them in the form of depot preparations (4 in the therapy group and 7 in the control group).

As would be expected after random treatment allocation, the main cognitive outcomes were similar in the two groups at baseline, as were social behaviour and self-esteem. However, despite randomisation, the level of symptoms appeared to be greater in the therapy group (Table 2), but this variable was already included as a covariate in all models considered. The baseline means for the other main and secondary outcomes are presented in Table 2. The NART scores were 92.7 (s.d.=13.3) for the therapy group and 92.4 (s.d.=12.7) for the control group.

---

**Fig. 1** Study profile.
Outcomes of therapy

Table 3 shows the group comparison results for all the outcomes. All statistically significant changes show an advantage for cognitive remediation. Working memory shows an improvement across both post-treatment time points and cognitive flexibility an improvement at the follow-up time point. Both differences are small to moderate effects. For working memory change the number needed to treat (NNT) is 3.1 to produce a clinical change of at least 2 points on the Digit Span test. For cognitive flexibility the NNT is 6.7 to improve by at least two categories on the WCST at follow-up.

Using the same mixed models analyses, drug effects were investigated using drug type as an additional explanatory variable. Neither working memory nor WCST outcomes were related to the type of medication prescribed (defined as either typical v. atypical or when depot preparations were considered). However, there was a significant drug x group interaction ($F_{12,70}=4.4, P=0.016$) for planning scores. Further investigation of these effects suggests that cognitive remediation therapy had an overall effect on planning for those who received either clozapine or typical medication that was absent for those who received other atypical medications.

Normal score attainment following therapy

The normal range for the main outcome tests was conservatively estimated from the test manuals. For working memory this was within 1 standard deviation of the mean normal score, for cognitive flexibility it was above the 5th percentile and for planning it was above the low average score.

For working memory there were 21 participants in the therapy group and 18 in the control group who had abnormal working memory scores at baseline. Following the intervention, there was an advantage to therapy which was significant at the post-therapy assessment but failed to reach significance at follow-up (post-treatment: 43 therapy v. 11% control, Fisher’s exact test $P=0.037$; follow-up: 32 therapy v. 7% control, Fisher’s exact test $P=0.10$). For cognitive flexibility there was no difference at either the post-treatment or the follow-up assessment (post-treatment: 15 therapy v. 17% control; follow-up: 17 therapy v. 21% control). For planning, although almost double the number of people in the therapy group had a normalised score, there was no statistically significant effect (post-treatment: 32 therapy v. 17% control; follow-up: 36 therapy v. 19% control).

Other outcomes

These analyses are designed to detect whether there is a direct effect of cognitive remediation therapy on functioning outcomes, irrespective of the level of cognitive improvement detected. The results of the analyses are shown in Table 3. For both symptoms and self-esteem the results were in the expected direction, with the therapy group improving compared with the control group at post-treatment. There was evidence of an interaction such that any differential improvement at the

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Antipsychotic medication provided at baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy group (n=43)</td>
<td>Control group (n=42)</td>
</tr>
<tr>
<td>Atypical medication, n</td>
<td></td>
</tr>
<tr>
<td>Clozapine</td>
<td>16</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>8</td>
</tr>
<tr>
<td>Risperidone</td>
<td>7</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>1</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>2</td>
</tr>
<tr>
<td>Typical medication</td>
<td></td>
</tr>
<tr>
<td>Mean dosage, mg CPZeq</td>
<td>368</td>
</tr>
<tr>
<td>CPZeq, chlorpromazine equivalent.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Cognitive, secondary and functioning outcome scores</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline assessment</td>
</tr>
<tr>
<td></td>
<td>CRT group</td>
</tr>
<tr>
<td></td>
<td>n</td>
</tr>
<tr>
<td>Memory (Digit Span)$^1$</td>
<td>43</td>
</tr>
<tr>
<td>Cognitive flexibility (WCST)$^2$</td>
<td>43</td>
</tr>
<tr>
<td>Planning (BADS)$^3$</td>
<td>43</td>
</tr>
<tr>
<td>Symptoms (PANSS)</td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td>43</td>
</tr>
<tr>
<td>Negative symptoms</td>
<td>43</td>
</tr>
<tr>
<td>Positive symptoms</td>
<td>43</td>
</tr>
<tr>
<td>Self-esteem (SES)</td>
<td>43</td>
</tr>
<tr>
<td>Social behaviour (SBS)</td>
<td>43</td>
</tr>
</tbody>
</table>

BADS, Behavioural Assessment of the Dysexecutive Syndrome; CRT, cognitive remediation therapy; PANSS, Positive and Negative Syndrome Scale; SES, Self-Esteem Scale; WCST, Wisconsin Card Sorting Test; SBS, Social Behaviour Scale.

1. Maximum score 30.
post-treatment assessment disappeared at follow-up. However, there was no evidence of a direct effect of therapy on social behaviour scores.

**Economic outcomes**

Total overall health and societal costs are shown in Table 4. There is an advantage (although with highly skewed confidence limits) for the treatment period, with a difference of UK £1086 in healthcare costs and £1284 in societal costs in favour of the therapy group, but costs are higher at follow-up. The intervention dominates at the post-treatment evaluation with both lower costs and a greater proportion of participants showing cognitive improvement (mean difference 21%, 95% CI 0–41). At follow-up, the cognitive advantage of the intervention therapy (mean difference 21%, 95% CI 2–41) needs to be considered against the additional costs. The cost-effectiveness ratios showed that for each additional 1% of ‘improvers’ in Digit Span (see Method) there was an additional cost of £46 in healthcare and social care costs and £24 in societal costs.

**Effects of cognitive improvement**

Since group could be shown to affect working memory, the effect of working memory change over the treatment period on social functioning outcome to follow-up was investigated using regression. There was no evidence of a group-dependent effect of cognition ($F=0.996$, d.f. = 1.65, $P=0.32$), but after excluding the interaction term there was a significant effect of cognitive change ($F=4.78$, d.f. = 1.66, $P=0.03$), suggesting that improvements in cognition were associated with improvements in social behaviour. When the effects were investigated in each group independently there was a significant effect for the therapy group ($F_{(1,13)}=9.2$, $P=0.005$) but not for the control group ($F_{(1,14)}=0.06$, $P=0.16$).

**DISCUSSION**

The participants in this study had a wider range of abilities than participants in other studies and most other clinical information showed a wide spread of scores. In the overall comparisons these wider ranges tended to produce differences in the direction of this sample having poorer performance (e.g. on the WCST and Digit Span). In fact, although the sample was recruited as having fulfilled a number of different cognitive criteria, a large proportion (30 v. 6%) did not complete any categories.

### Table 3 Mixed effects models analysis

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Interaction</th>
<th>Group effect (excluding non-significant interaction)</th>
<th>Estimated advantage to CRT</th>
<th>Standardised effect size$^1$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$F_{(0,2i)}=0.21, P=0.84$</td>
<td>$F_{(0,2i)}=5.82, P=0.019$</td>
<td>1.33 (0.43 to 2.16)</td>
</tr>
<tr>
<td>Primary outcomes</td>
<td></td>
<td>$F_{(0,4i)}=6.924, P=0.011$</td>
<td>NA</td>
<td>0.17 (−0.64 to 0.98)</td>
</tr>
<tr>
<td>Working memory (Digit Span)</td>
<td>$F_{(0,7i)}=0.315, P=0.576$</td>
<td>$F_{(0,7i)}=2.9, P=0.092$</td>
<td>1.1 (−0.18 to 2.4)</td>
<td>1.05 (−0.3 to 2.42)</td>
</tr>
<tr>
<td>Cognitive flexibility (WCST)</td>
<td>$F_{(0,4i)}=4.44, P=0.039$</td>
<td>NA</td>
<td>1.05 (−0.3 to 2.42)</td>
<td>0.57 (−1.99 to 0.85)</td>
</tr>
<tr>
<td>Post-treatment</td>
<td>$F_{(0,1i)}=3.55, P=0.06$</td>
<td>NA</td>
<td>−0.57 (−1.99 to 0.85)</td>
<td>−4.68 (−10.81 to 1.44)</td>
</tr>
<tr>
<td>Follow-up</td>
<td>$F_{(0,3i)}=0.438, P=0.51$</td>
<td>$F_{(0,3i)}=0.008, P=0.029$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Planning (BADS)</td>
<td>$F_{(0,3i)}=0.576$</td>
<td>$F_{(0,3i)}=0.092$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>$F_{(0,1i)}=1.99, P=0.18$</td>
<td>$F_{(0,1i)}=0.85$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Self-esteem (SES)</td>
<td>$F_{(0,1i)}=1.99$</td>
<td>$F_{(0,1i)}=0.85$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Post-treatment</td>
<td>$F_{(0,2i)}=3.55$, $P=0.06$</td>
<td>NA</td>
<td>−0.57 (−1.99 to 0.85)</td>
<td>−4.68 (−10.81 to 1.44)</td>
</tr>
<tr>
<td>Follow-up</td>
<td>$F_{(0,3i)}=0.438, P=0.51$</td>
<td>$F_{(0,3i)}=0.008, P=0.029$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Symptoms (PANSS)</td>
<td>$F_{(0,7i)}=2.9, P=0.092$</td>
<td>1.1 (−0.18 to 2.4)</td>
<td>1.05 (−0.3 to 2.42)</td>
<td>0.57 (−1.99 to 0.85)</td>
</tr>
<tr>
<td>Post-treatment</td>
<td>$F_{(0,3i)}=0.008, P=0.029$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
<td></td>
</tr>
<tr>
<td>Follow-up</td>
<td>$F_{(0,3i)}=0.438, P=0.51$</td>
<td>$F_{(0,3i)}=0.008, P=0.029$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
<tr>
<td>Social functioning</td>
<td>$F_{(0,1i)}=1.99, P=0.18$</td>
<td>$F_{(0,1i)}=0.85$</td>
<td>0.18 to 2.4</td>
<td>0.18 to 2.4</td>
</tr>
</tbody>
</table>

| Table 4 Baseline-adjusted mean costs and mean cost differences, including the cost of CRT |
|----------------|----------------|----------------|
| CRT | Usual care | Mean difference$^1$ |
| $n$ | Cost, £ Mean (s.d.) | $n$ | Cost, £ Mean (s.d.) | £ (95% CI) |
| Post-treatment | | | | |
| Health/social care costs | 41 | 7756 (5936) | 39 | 8271 (7494) | −1086 (−3146 to 1152) |
| Societal costs | 41 | 8868 (5849) | 39 | 9497 (7413) | −1284 (−3348 to 942) |
| Follow-up | | | | |
| Health/social care costs | 41 | 15 639 (12 453) | 37 | 13 426 (12 852) | 975 (−3330 to 5255) |
| Societal costs | 41 | 17 586 (12 197) | 37 | 15 735 (12 654) | 494 (−3564 to 4577) |

1. Estimated advantage to CRT (95% CI)

BADS, Behavioural Assessment of Dysexecutive Syndrome; CRT, cognitive remediation therapy; NA, not applicable; PANSS, Positive and Negative Syndrome Scale; SES, Self-Esteem Scale; WCST, Wisconsin Card Sorting Test.

1. Number of points on outcome measure scale.

2. Effect/baseline s.d.
of the WCST unlike participants in an ear-
erly study (Wykes et al., 1999). The current
group had also been in contact with psychi-
atriac services for slightly longer and had
poorer cognitive capacity than the previous
study group (NART IQ 93 v. 104). Thus
the sampling method achieved a wider var-
iation in scores, with more people who had
particularly poor cognitive performance on
the outcome measures.

Despite the more chronic nature of im-
paired functioning in this sample, the re-
sults were similar to those of the previous
pilot study. There was a durable improve-
ment in working memory 6 months after
the end of therapy, a significant improve-
ment at follow-up in cognitive flexibility,
and an advantage – but not a significant
one – for planning (before medication was
taken into account). Thus, for the primary
cognitive outcomes there is evidence of
overall effectiveness in a mixed group of
participants, which in itself is an achieve-
ment as all the data point to a stable course
for cognitive deficits. This fits into the
growing evidence base showing that im-
provements in cognition are achievable
even when the disorder has been evident
for some time. In fact, nearly half of the
people who scored at a very poor level on
working memory performed within the
normal range following therapy.

Following the end of therapy there was
a continuing improvement in cognition, in
cognitive flexibility. One possible explana-
tion is that cognitive remediation therapy
‘jump starts’ engagement in the cognitive
system through enhancing positive reward.
This is achieved by the reinforcing nature
of the tasks; the encouragement within
therapy to engage these cognitive systems
in everyday tasks; and the improved
self-esteem and self-efficacy that further
encourage engagement in new tasks, which
provides continued practice.

The type of medication prescribed did
not have any effect on the WCST or Digit
Span outcomes. However, for the planning
measure there was a significant group by
medication interaction, suggesting that for
some cognitive outcomes the type of medi-
cation could hinder or enhance the effects
of cognitive remediation. The participants
prescribed clozapine had a lower baseline
planning score and therefore more chance
for improvement. On the other hand, there
was no difference in cognitive outcome
between those taking typical and those
taking atypical antipsychotics, suggesting
that atypical medication does have a
detrimental effect on the likelihood of
change due to cognitive remediation.

In addition to cognitive outcomes, there
were also some notable improvements in
distal outcomes such as self-esteem post-
treatment. These effects fit into the growing
pattern (described by Twamley et al., 2003)
of an effect on functioning of successful
cognitive rehabilitation. There was an
advantage in terms of both healthcare and
societal costs for the therapy group at the
post-treatment assessment, although this
was not significant.

Methodological considerations
Data from other studies demonstrate high
levels of stability of cognitive functioning
without an intervention (Greig et al.,
2004) and it might be proposed that these
cognitive effects result only from attention
and increased social contact. However,
they are similar to those found in a previous
trial in which there was an attention con-
trol group (Wykes et al., 1999, 2003), and
although levels of social contact were
higher in the therapy group there was no
direct effect on social functioning out-
comes. It therefore seems parsimonious to
assume that the intervention therapy did
produce the beneficial cognitive effects.

It is also vital to consider any possible
challenges to the study validity, which for
studies of psychological interventions in
particular include rater bias. Although pro-
cedures were in place to reduce the chance
of unmasking group allocation this did hap-
pen in some cases when cognitive data were
collected. However, data quality checks
(double scoring, data entry checking, etc.)
were carried out each month to ensure that
data were not obviously biased for any one
rater or for any one participant. It was not
possible to mask group allocation for the
social functioning informants, but in this
case there was no measurable effect of
therapy, only interactions with cognitive
improvements that were unknown to the
key informants when they were providing
the relevant information. It therefore seems
likely that these acknowledged methodo-
logical difficulties did not compromise
the study validity.

The sample size was small (although
larger than any prior studies of this ther-
apy) and so the power to investigate subtle
effects was low. However, if this therapy is
to be provided by health services it needs to
show at least moderate effects and the
current effect sizes are similar to those
attributed to cognitive–behavioural therapy
(Tarrier & Wykes, 2004) suggesting that
they may have some clinical relevance.

The effects of improving working
memory
Poor memory has been highlighted in a
number of studies as predicting poor over-
all outcome (Mueser et al., 1991; Green et
al., 2000). It was assumed that cognitive
improvements would lead to functional
change, and this is one of the reasons that
cognitive remediation therapy was de-
veloped. However, few studies have measured
the functional effects at a time when it
might be possible for cognitive improve-
ment to have had time to translate into
functional changes. In this study there was
support for a model in which a change in
working memory had a beneficial effect
on social behaviour 6 months after the
end of therapy. This effect was only signifi-
cant in the therapy group. The intervention
was associated with lower costs at post-
treatment assessment, and even when there
were higher costs at follow-up these were
small in relation to the beneficial outcome
in working memory. The therapy itself has
been estimated to cost £546.97 at 2000–
2001 prices per patient (Wykes et al.,
2003). The cost-effectiveness analysis has
demonstrated that this translates into a
small price to pay for memory improve-
ments which are likely to produce further
benefits on social behaviour.

The mechanisms through which cogni-
tive change leads to functioning change
have been somewhat elusive. Wykes &
Reeder (2005) have suggested that for
change to occur in routine behaviours, cog-
nitive capacity of the sort measured by neu-ropsychological tests must change. This
increases the efficiency with which routine
cognitive schemas are implemented or held
online. However, most functioning is not
routine and must be flexible, so for novel
behaviours it is necessary to change a
further aspect of thinking – metacognition.
Metacognitive processes and knowledge are
required for the replacement of inefficient
existing routine schemas and for the pro-
duction of new, temporary high-level sche-
mas. Current measures of cognition do
not allow the separation of cognitive from
metacognitive processes, and current mea-
sures of functioning also do not allow the
differentiation of routine from novel actions.
It is possible that the incomplete translation
of working memory improvements into
social behaviour change is explained by the fact that it is not currently possible to differentiate the two forms of action. Working memory improvements are likely to translate into routine actions immediately, but not necessarily directly to non-routine actions unless metacognition has also improved. Future studies need to be able to differentiate behaviour change into routine behaviour efficiency and novel behaviour flexibility.

ACKNOWLEDGEMENTS

The study was supported by a grant from the Department of Health (RFG 757) who had no role in the study design, data analysis or interpretation, writing the report or decision to submit the paper for publication. The views expressed in this paper are those of the authors and not necessarily those of the funder.

REFERENCES


